Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa
- PMID: 29308013
- PMCID: PMC5751912
- DOI: 10.1177/1178633717749597
Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa
Abstract
There has been tremendous breakthrough in the development of technologies and protocols for counselling, testing, and surveillance of resistant human immunodeficiency virus strains for efficient prognosis and clinical management aimed at improving the quality of life of infected persons. However, we have not arrived at a point where services rendered using these technologies can be made affordable and accessible to resource-limited settings. There are several technologies for monitoring antiretroviral resistance, each with unique merits and demerits. In this study, we review the strengths and limitations of prospective and affordable technologies with emphasis on those that could be used in resource-limited settings.
Keywords: Antiretroviral resistance; HIV/AIDS; laboratory technology.
Conflict of interest statement
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.AIDS Rev. 2017 Oct-Dec;19(4):219-230. AIDS Rev. 2017. PMID: 28182618 Review.
-
Immune status monitoring of HIV/AIDS patients in resource-limited settings: a review with an emphasis on CD4+ T-lymphocyte determination.Asian Pac J Allergy Immunol. 2012 Mar;30(1):11-25. Asian Pac J Allergy Immunol. 2012. PMID: 22523903 Review.
-
Very early virological failure and drug resistance mutations in a woman on antiretroviral therapy in Eastern Cape, South Africa: a case report.J Med Case Rep. 2015 May 7;9:106. doi: 10.1186/s13256-015-0557-0. J Med Case Rep. 2015. PMID: 25947544 Free PMC article.
-
A Quality Management Approach to Implementing Point-of-Care Technologies for HIV Diagnosis and Monitoring in Sub-Saharan Africa.J Trop Med. 2012;2012:651927. doi: 10.1155/2012/651927. Epub 2012 Jan 11. J Trop Med. 2012. PMID: 22287974 Free PMC article.
-
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.Lancet Infect Dis. 2016 Nov;16(11):e267-e275. doi: 10.1016/S1473-3099(16)30118-9. Epub 2016 Aug 25. Lancet Infect Dis. 2016. PMID: 27569762
Cited by
-
Antiretroviral (ARV) Drug Resistance and HIV-1 Subtypes among Injecting Drug Users in the Coastal Region of Kenya.Adv Virol. 2022 Feb 10;2022:3217749. doi: 10.1155/2022/3217749. eCollection 2022. Adv Virol. 2022. PMID: 35186083 Free PMC article.
-
Bayesian variable selection using Knockoffs with applications to genomics.Comput Stat. 2022 Sep 18:1-20. doi: 10.1007/s00180-022-01283-8. Online ahead of print. Comput Stat. 2022. PMID: 36157067 Free PMC article.
-
Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV.Viruses. 2024 Oct 30;16(11):1697. doi: 10.3390/v16111697. Viruses. 2024. PMID: 39599811 Free PMC article. Review.
-
3-Hydroxyphthalic Anhydride- Modified Rabbit Anti-PAP IgG as a Potential Bifunctional HIV-1 Entry Inhibitor.Front Microbiol. 2018 Jun 19;9:1330. doi: 10.3389/fmicb.2018.01330. eCollection 2018. Front Microbiol. 2018. PMID: 29971062 Free PMC article.
-
"I feel drug resistance testing allowed us to make an informed decision": qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya.BMC Health Serv Res. 2023 Aug 24;23(1):908. doi: 10.1186/s12913-023-09804-x. BMC Health Serv Res. 2023. PMID: 37620855 Free PMC article. Clinical Trial.
References
-
- Centre for Disease Control and Prevention. HIV/AIDS. www.cdc.gov/hiv/default.html. Accessed July 20, 2017.
-
- De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33:307–320. - PubMed
-
- De Clercq E. Human viral diseases: what is next for antiviral drug discovery? Curr Opin Virol 2012;2:572–579. - PubMed
-
- World Health Organization. What’s new in treatment monitoring: viral load and CD4 testing. 2017. http://www.who.int/hiv/pub/arv/treatment-monitoring-info-2017/en/.
-
- Inzaule SC, Hamers RL, Paredes R, Yang C, Schuurman R, Rinke de Wit TF. The evolving landscape of HIV drug resistance diagnostics for expanding testing in resource-limited settings [published online ahead of print February 9, 2017]. AIDS Rev. PMID:28182618. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources